Abiomed Paves Bridge-To-Recovery Market On Road To Destination Therapy
This article was originally published in The Gray Sheet
Executive Summary
Abiomed is refocusing its ventricular-assist device (VAD) sales efforts on open-heart surgery instead of transplant centers to climb out of an unprofitable quarter and sequential loss of revenue
You may also be interested in...
Study Suggests LVAD As Platform For Mending Late-Stage Heart Failure
Left ventricular assist devices might function as a platform for revitalizing hearts previously considered beyond repair, according to a study in the Nov. 2 New England Journal of Medicine
Study Suggests LVAD As Platform For Mending Late-Stage Heart Failure
Left ventricular assist devices might function as a platform for revitalizing hearts previously considered beyond repair, according to a study in the Nov. 2 New England Journal of Medicine
New Thoratec Chief Burbach Sees No Need For Major Change
Thoratec's new president and CEO says he is not looking to make any sweeping changes in company operations, at least not in the near term